The Therapeutic Optimisation Company
The future of healthcare is not just about creating better medicines. It is about achieving the best possible outcome from every medicine, for every patient.
Therapeutic Optimisation is the missing category in the pharmaceutical value chain.
- 1
Discovery and Preclinical
Identify targets and develop candidate molecules
CROs and Research Partners
- 2
Clinical Development
Evaluate safety and efficacy in clinical trials
CROs and Clinical Trial Services
- 3
Manufacturing
Scale and produce the medicine to regulatory quality standards
CDMOs and CMOs
- 4
Commercialisation and Launch
Bring the medicine to market and drive adoption
Commercial, market access and medical affairs partners
- 5
Distribution and Access
Ensure supply to patients and providers
Wholesalers, pharmacies and logistics providers
- 6
Post Market Use (Real world)
The medicine is prescribed and used in routine clinical practice
Therapeutic Optimisation Industry
No established industry exists today to systematically optimise how medicines perform after approval.
CROs became indispensable to getting medicines approved. Therapeutic Optimisation is how medicines fulfil their potential once they are.
A medicine’s efficacy in clinical trials is not always matched by its effectiveness in clinical practice
Clinical trials are a controlled environment
Clinical trials create optimal conditions: the right patient, the right dose, active monitoring of side effects and structured adherence support.
Clinical practice is not optimised
Outside the trial setting, follow-up is limited, adherence varies, patients discontinue treatment, and side effects and adverse events are missed. Patients do not always receive the correct dose, and the benefit observed in trials can fall by as much as half.
$2.3tn
forecast global spend on medicines by 2028
~50%
of patients with chronic disease do not take long-term therapies as prescribed
$100–300bn
annual US healthcare cost of medication non-adherence alone
Unlocking the potential of every medicine
A continuous layer of intelligence and care that closes the gap between what a medicine can do and what it actually does.
Monitor
Continuous signal, not episodic snapshots
Understand
Interpret what changed and why it matters
Personalise
Adapt the treatment plan as the patient’s needs change
Intervene
Intervene clinically at the point of change
Learn and Improve
Every decision strengthens the next
Condition-agnostic. Medicine-specific.
Every patient is different. They respond differently, their circumstances change, and their treatment needs to change with them. Optimisation is the work of noticing that change and acting on it, continuously, safely, and at a scale clinical workforces cannot reach alone.
The opportunity is clear. The capability to deliver it is here.
Wearables make patients observable
Connected medical devices turn episodic clinical encounters into continuous physiological data. Linked to the patient record, that data becomes clinically actionable.
AI makes it possible
AI can analyse complex patient data, personalise support and coordinate clinical intervention at a scale no clinical workforce can match.
The patient relationship is changing
As medicines become more complex, pharmaceutical companies face rising expectations from patients and payers alike. Value is increasingly judged by the outcomes a medicine achieves in practice, which requires ongoing, personalised support and real-world evidence of value.
Built from clinical excellence in the real-world
Healthcare has a chronic disease problem that existing delivery models cannot scale to solve. In 2020, we recognised that the solution would require a new clinical operating model rather than simply another digital health app. We built the platform before the market demanded it. The emergence of GLP-1 therapies has now created that demand and provided proof of concept.
Patented Innovation. Lasting differentiation
We are not only building a clinical business. We are building the foundations for what healthcare will become.
Reset Therapeutic Optimisation Platform
U.S. Patent No. 12,770733 B2, granted October 2026
Covers the technology required to recognise when a patient's condition changes, and to use intelligence to determine what happens next — classifying patients, monitoring change and continuously evolving treatment plans.
Autonomyx
Patent Pending
AI operating system for precision therapeutics - composable modules that transform physiological patterns into personalized treatment decisions across any intervention.
One platform. Four ways to work with us.
Managed Programmes
End-to-end Therapeutic Optimisation programmes, delivered by Reset Health’s clinical teams and supported by agentic AI.
Platform Licensing
Our AI-enabled platform, licensed to healthcare providers and pharmaceutical partners.
White-Label Infrastructure
Clinical and digital infrastructure on which partners can launch their own branded direct-to-patient services.
IP Licensing
License Reset Health’s intellectual property to operate your own model, with freedom to operate on protected ground.
Evidence, Regulation and Partners
Roczen®, the first proof of the model for incretin-based therapies
Founded and led by NHS obesity specialists, Roczen® applied Therapeutic Optimisation to the fastest-scaling therapy class in modern medicine.
It is where the model was proven in clinical practice, across complex patient populations, with measurable outcomes. It is the first application, not the limit.
Quality and Safety Assured
Roczen® has been evaluated by NICE for delivering multidisciplinary weight-management services and for prescribing and monitoring weight-management medicine. The outcome is a time-limited NICE recommendation for early use within the NHS until March 2028, while further evidence is gathered.
Patients
Personalised, continuous clinical care that improves treatment outcomes and persistence.
Clinicians
Clinical expertise extended to significantly more patients, without diluting the standard of care.
Healthcare systems
Safe, effective care that scales without a proportional increase in workforce, while reducing cost and waste.
Pharmaceutical companies
Medicines that achieve their full therapeutic and commercial potential in clinical practice.
Scaling clinical intelligence globally
Global Clinical Expertise. Local Solutions. Designed in Partnership.
Reset Health is the Therapeutic Optimisation company, the missing infrastructure that ensures medicines deliver their intended outcomes once they reach the market. We partner with healthcare systems across the United States, the United Kingdom, Malaysia and Europe, combining multidisciplinary clinical teams, structured governance and patented technology into programmes co-designed to fit existing pathways and deliver measurable results at scale.
